IFNB1 and neoplasm: Later in 2011, the potentiating effect of romurtide was discovered: its co-administration with IFN-β promotes the maturation of dendritic cells and inhibits the growth of B16F10 melanoma, while muramyl peptide and IFN-β alone did not have a significant effect on tumor growth (89).